A Trial of CM-AT in Children With Autism

PHASE3CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

September 30, 2011

Conditions
Autism
Interventions
DRUG

CM-AT

Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days

DRUG

Placebo

Single unit dose powder of non-active substance administered 3 times per day for 90 days

Trial Locations (19)

10029

Mount Sinai School of Medicine, New York

15260

University of Pittsburgh, Pittsburgh

17033

Hershey Medical Center, Hershey

19124

Drexel University, Philadelphia

27514

University of North Carolina, Chapel Hill

30080

Institute for Behavioral Medicine, Smyrna

32763

Lake Mary Pediatrics, Orange City

43210

Ohio State University, Columbus

60169

Alexian Brothers Center for Psychiatric Research, Hoffman Estates

71103

Louisiana State University Health Science Center, Shreveport

73117

Oklahoma University Child Study Center, Oklahoma City

77054

University of Texas, Houston, Houston

84015

Westside Medical, Clinton

85006

Southwest Autism Research and Resource Center, Phoenix

92701

Neuropsychiatric Research Center of Orange County, Santa Ana

94143

University of California, San Francisco, San Francisco

95817

University of California, Davis, M.I.N.D. Institute, Sacramento

97030

Cyn3rgy Research, Gresham

08901

Saint Peters University Hospital, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Curemark

INDUSTRY

NCT00881452 - A Trial of CM-AT in Children With Autism | Biotech Hunter | Biotech Hunter